Citations

Clear

3485 citation(s) found for "Sy, Sarah".

DPYD Sequencing Identifies More Clinically Relevant Variants as Compared to Targeted Genotyping
Moyer, A. M., Lundquist, Emma, Thoreson, Emily , Kluge, Michelle L. , Kotzer, Katrina E. , Love, Elyse M, Glessner, Heather L, Arneson, Sarah, Langman, Loralie J., Baudhuin, Linnea M. , Black, John Logan, Moyer, AM , Thoreson, Emily K, Arneson, Sarah K, Lundquist, Emma L., Love, Elyse M., Glessner, Heather Dean, Black, John L.

Mayo Clinic

Clinical Chemistry | January 13, 2026 | Volume: 72 | Issue: 6 | Pages: 662-669

10.1093/clinchem/hvag007 | PMID 41802113 Get It

Abstract Background DPYD testing can identify patients at risk for severe toxicity when a standard fluoropyrimidine antineoplastic dose is prescribed. Sequencing-based methods detect rare variants, which require classification. Methods DPYD sequencing results over a 9-year period through to 2024 were analyzed. The dataset was filtered to calculate the positive test rate for different genotyping strategies, including targeted analysis of the Association for Molecular Pathology (AMP) Tier 1 and 2 recommended alleles, and as compared to sequencing. Variant classifications based on the laboratory’s clinical protocol were compared to ClinVar classifications and designations by the Clinical Pharmacogenetics Implementation Consortium (CPIC) expert panel. Results A DPYD variant was reported in 12.79% (896/7003) of those tested, with 2.53% (170/7003) of all reports including a variant of uncertain significance. Had only AMP Tier 1 or both Tier 1 and 2 been tested, 9.30% and 9.44% of patients would have received a positive report, respectively. Among the 281 unique, non-Tier 1/Tier 2 variants encountered during sequencing, >80% were not classified by the CPIC expert panel, while >48% were not reported in ClinVar. Variant classifications by our laboratory and those in ClinVar were generally concordant with the CPIC expert panel, despite the lack of a standardized classification system. Conclusions While AMP Tier 1 genotyping would have identified most patients at risk for fluoropyrimidine toxicity, sequencing is more comprehensive, identifying 26% more reportable variants compared to targeted genotyping. A standard framework for pharmacogenomic variant classification could facilitate consistent variant classification and a transition from targeted genotyping to sequencing.
Phase II study of tinengotinib in advanced cholangiocarcinoma: Analysis of molecular response and resistance mechanisms.
Lamarca, Angela, Javle, Milind M., Fountzilas, C., Liao, Chih-Yi, Pelster, Meredith , Deming, Dustin A. , Sahai, Vaibhav , Fonkoua, Lionel Aurelien Kankeu, Cohn, Allen Lee, Mantry, Parvez , Richards, D., Kingsley, Ed, Mahipal, A., Hennessy, Katie , Wang, Hui , Sun, Caixia , Sahai, Vaibhav , Lamarca, Angela , Javle, Milind , Fountzilas, Christos , Liao, Chih‐Yi , Li, Daneng , Fonkoua, Lionel Aurelien Kankeu , Mahipal, Amit , Fan, Jean

Mayo Clinic

Journal of Clinical Oncology | January 12, 2026 | Volume: 44 | Issue: 2_suppl | Pages: 566-566

10.1200/jco.2026.44.2_suppl.566 Get It

566 Background: FGFR inhibitors (FGFRi) have an established role in treating FGFR2-altered (alt) cholangiocarcinoma (CCA). Tinengotinib, a novel FGFRi, has shown promising activity overcoming acquired resistance to prior FGFRi. We present biomarker analyses evaluating tinengotinib’s ability to overcome prior FGFRi resistance and to elucidate mechanism of resistance to tinengotinib. Methods: Eligible patients (pts) with advanced/metastatic CCA who had received ≥ 1 prior systemic chemotherapy were treated with tinengotinib 10 mg daily across 4 Cohorts: A1: FGFR2 fusion (fus) with primary progressive disease (PD) on prior FGFRi; A2: FGFR2 fus with PD after prior response to FGFRi; B: FGFR alt without FGFR2 fus; C: FGFR wild-type. Efficacy was assessed by RECIST v1.1. All pts underwent liquid biopsy for circulating tumor DNA (ctDNA) at baseline; additional timepoints include cycle 3 day 1 (C3D1), time of PD, and end of treatment (EOT). Samples were analyzed using FoundationOne Liquid panel. Results: 27 out of 55 enrolled pts had biomarker samples collected at baseline and C3D1. Among them, pts in A1 (n=10, 107 mutations (mut)), B (n=8, 90 mut) and C (n=5, 74 mut) showed a significant decrease in short variant allele frequencies (VAF) from baseline to C3D1 by a median relative VAF reduction of 100% (p<0.0001) for each of the three cohorts. Although a median relative VAF reduction of 33.3% was seen in A2 (n=4, 15 mut), this was not significant (p=0.6093) likely due to low baseline mutation burden. A ≥50% reduction in ctDNA was associated with improved progression free survival (p<0.0014). Additionally, 100% of median relative reductions in FGFR2 kinase domain (KD) mut were seen in A1 and B (p<0.0001, 95% CI 100-100% and p=0.0156, 95% CI 83.6-100%, respectively), with 92% and 57% clearance of initial FGFR2 KD mut by C3D1. In a subgroup of 10 pts with biomarker sampling at baseline and EOT, 3 pts in A1 with acquired resistance showed emergence of novel FGFR2 mut, loss of FGFR-sensitive mut and new mut in alternate pathways (e.g., AKT, EGFR, RAS/MAPK) while retaining the original FGFR2 fus. 1 pt from B developed resistance due to new FGFR2 rearrangements and FGFR2 mut. 4 FGFR wild-type pts from C developed resistance involving mut in TP53, KRAS, and other oncogenic drivers. Conclusions: These findings provide genomic evidence that tinengotinib may overcome resistance to prior FGFRi treatment in FGFR2 fus-positive CCA, as reflected by significantly reductions in ctDNA VAFs and frequent clearance of FGFR2 KD mutations. The emergence of resistance alterations including de novo FGFR2 mutations and bypass pathways activations indicates acquired resistance that may limit long-term benefit. These results support further investigation with expanded biomarker sampling to better characterize resistance evolution and guide therapy optimization in an ongoing Phase 3 trial. Clinical trial information: NCT04919642 .
P-1848. Outpatient Parenteral Antimicrobial Therapy: How Adherence to Best Practices Shapes Patient Outcomes
Ward, Autumn, Stakston, Jaclyn , Cai, Songlin , Treu, M., Puent, Kevin, Dierkhising, Ross, Lessard, Sarah , Treu, Megan L, Dierkhising, Ross, Dababneh, Ala S.

Mayo Clinic

Open Forum Infectious Diseases | January 12, 2026 | Volume: 13 | Issue: Supplement_1 | Pages: No page available

10.1093/ofid/ofaf695.2017 Get It

Abstract Background Outpatient parenteral antimicrobial therapy (OPAT) allows patients to complete extended antimicrobial treatment at home, improving quality of life and reducing healthcare costs. National guidelines outline best practices for antimicrobial administration, vascular access management, monitoring, and recommend involving an infectious disease physician and a multidisciplinary team. Evaluating adherence to these practices can identify improvement opportunities and enhance outcomes. The primary objective of this study was to assess patient outcomes related to adherence to OPAT best practices at Mayo Clinic Health System – Southwest Wisconsin (MCHS–SWWI). Secondary objectives included evaluating adherence to key process metrics and identifying associations between baseline characteristics and outcomes. Methods This retrospective cohort study included adults discharged from MCHS–SWWI on home OPAT from November 2021 to July 2024. Patients were excluded if under 18 years old or if they received OPAT in non-home settings (e.g., skilled nursing, infusion center). Data on process metrics, outcomes, and safety were collected through manual chart review. These findings were evaluated against established best practices to assess the OPAT program's adherence and determine the impact of this adherence on patient outcomes. Statistical analysis used Pearson’s chi-square tests and Wilcoxon rank sum tests to measure associations of patient characteristics with outcomes. Results A total of 164 patients were included. The MCHS-SWWI OPAT program demonstrated high adherence ( &gt; 85%) to majority of established best practices. Successful OPAT completion occurred in 92.7% of patients, and overall incidence of adverse events and poor outcomes was generally low. Adherence to best practices was below 85% for vascular access selection (81.7%) and completion of weekly labs and vascular access care throughout the OPAT course (∼69%). Conclusion High adherence to OPAT best practices led to a generally low incidence of adverse events, treatment failures, and other unfavorable patient outcomes. The results of this study provide valuable insights to guide institutional quality improvement initiatives aimed at optimizing patient outcomes in OPAT therapy through targeted interventions. Disclosures All Authors: No reported disclosures
Voice and Speech in Atypical Parkinsonian Disorders
Rodríguez‐Porcel, Federico , Ali, Farwa, Bruno, Michiko Kimura , Cuevas, Heather Davis, Dhall, Rohit , Dunne‐Platero, Kylie, Golbe, Lawrence I., Haq, Ihtsham, Herndon, Nicole E. , Honig, Lawrence S., Kang, Kyurim , Kremen, Sarah , Lamotte, Guillaume, Mir, Michela , Montaser‐Kouhsari, Leila , Page, Joel, Pickett, Hylan, Verdun, Laura Purcell, Richardson, Kelly , Shurer, Jessica , Troche, Michelle, Utianski, Rene L., Villarreal‐Cavazos, Katya , Wills, Anne‐Marie , Bruno, Michiko K , McFarland, Nikolaus R , Pantelyat, Alex , Virmani, Tuhin , Kremen, Sarah , Ali, Farwa , Dunne-Platero, Kylie E., Haq, Ihtsham , Honig, Lawrence S. , Lamotte, Guillaume , McFarland, Nikolaus R. , Pantelyat, Alexander , Troche, Michelle S. , Utianski, Rene L.

Mayo Clinic

Movement Disorders Clinical Practice | January 10, 2026 | Volume: 13 | Issue: 8 | Pages: 1848-1860

10.1002/mdc3.70515 | PMID 41518136 Get It

Background Motor speech disorders are early, common, and functionally limiting features of atypical parkinsonian disorders (APDs) such as progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), and multiple system atrophy (MSA). These impairments are underrecognized and undertreated in neurology clinics. Objectives This review aims to characterize speech impairment in APDs, offer practical guidance for clinical evaluation, highlight the role of Speech‐Language pathologists (SLPs) in diagnosis and management, and outline current and emerging management strategies. Methods A narrative review was conducted by the Diagnosis and Treatment Working Group of CurePSP's Centers of Care, integrating literature and clinical experience to summarize evaluation, diagnosis, and treatment of motor speech disorders in APDs. Results Speech changes in APDs are often mixed dysarthrias with hypokinetic, spastic, and/or ataxic components, and may include apraxia of speech; these are frequently more severe and progress quicker than in Parkinson's disease. These features can assist in differential diagnosis and should prompt early referral to SLPs. Despite the high prevalence of speech and voice changes, comprehensive assessment of motor speech disorders is uncommon in neurology clinics. Current evidence regarding the efficacy of interventions is mixed. Digital acoustic analysis and neuromodulation offer promising directions for diagnosis and treatment. Conclusions Early, collaborative management of motor speech impairment elevates care in APDs. Neurologists and SLPs must work together to improve recognition, diagnosis, and care. Future research should focus on objective biomarkers and personalized therapies to support communication, autonomy, and quality of life for individuals living with APDs.
The utility of plasma p ‐tau217 in former American football players at risk for chronic traumatic encephalopathy
Miner, Annalise E. , Ashton, Nicholas J., Zetterberg, Henrik, Blennow, K., Groh, Jenna R., Tripodis, Yorghos, Adler, Charles, Balcer, Laura Joan, Bernick, Charles , Peskind, Elaine R. , Rabinovici, Gil D., Banks, Sarah J, Barr, William B., Dodick, David W., Mez, Jesse, Palmisano, Joseph N., Martin, Brett, Stein, Thor D., McKee, Ann C., Cummings, J. R. , Shenton, Martha E., Em, Reiman, Stern, Robert A., Alosco, Michael L, Ashton, Nicholas J. , Zetterberg, Henrik , Blennow, Kaj , Groh, Jenna R. , Tripodis, Yorghos , Adler, Charles, Asken, Breton M. , Tanner, Jeremy A. , Rabinovici, Gil D. , Banks, Sarah J. , Barr, William , Wethe, Jennifer V. , Cantu, Robert C. , Dodick, David W. , Mez, Jesse , Palmisano, Joseph , Stein, Thor D. , McKee, Ann C. , Cummings, Jeffrey L., Shenton, Martha E. , Alosco, Michael L.

Mayo Clinic

Alzheimer's & Dementia | January 10, 2026 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_105546 Get It

Abstract Background In vivo biomarkers that can detect long‐term neuropathologies from repetitive head impact (RHI) exposure are needed, especially for the neurodegenerative tauopathy chronic traumatic encephalopathy (CTE). Here, we evaluated plasma p ‐tau217 as a potential biomarker for CTE p ‐tau pathology, and examined the concordance between plasma p ‐tau217 and Aβ pathology in an at‐risk for CTE sample. Method The sample included 180 male former football players (120 professional, 60 college), and 56 asymptomatic men without RHI (i.e., controls). Participants completed blood draws, 18F‐florbetapir (Aβ+=SUVR≥1.10), and 18F‐flortaucipir PET. Traumatic encephalopathy syndrome (TES) diagnoses were made. Single molecule array for plasma p ‐tau217 (ALZpath) was performed (≥0.6 cutoff used to maximize sensitivity). Nine participants had post‐mortem tissue. ANCOVA examined group differences in p ‐tau217 (football vs controls; TES‐CTE no, TES‐CTE suggestive, TES‐CTE possible/probable). Multivariable regression models tested associations between p ‐tau217 and florbetapir/flortaucipir PET. Covariates included age, race and APOE e4 . Result Sample characteristics are in Table 1. p ‐tau217 concentrations were higher in former football players compared to controls (est. marginal mean difference=‐0.217, p = 0.005). There were no group differences in Aβ‐PET SUVR. No differences were found across TES‐CTE certainty levels. In football players, higher p ‐tau217 was associated with higher Aβ‐PET SUVR (B=1.380, 95%CI[0.597‐2.155], p = 0.001) but not when Aβ+ ( n = 17) participants and those with kidney/liver disease ( n = 5) were excluded. Aβ+ participants had the highest p ‐tau217 (Figure 1). When compared against Aβ‐PET, several false Aβ‐positives (high p ‐tau217, Aβ‐) were identified, including one extreme outlier (assay related) and a cluster of Aβ‐ participants with p ‐tau217 between 0.60–1.0. There were no associations with flortaucipir SUVR (frontal, mesial temporal, left parietal). Two extreme p ‐tau217 outliers had autopsy‐confirmed CTE stage III (AD‐, Table 2). Of the remaining donors, all were AD‐ and four had CTE (stages II‐IV) with ptau217 between 0.125‐0.449. Conclusion Plasma p ‐tau217 has usefulness in quantifying Aβ pathology but restricted utility for detection of CTE. In this at‐risk for CTE sample, p ‐tau217 and Aβ‐PET were associated at the group level. At the individual level, false Aβ‐positives (and negatives) existed, including Aβ‐ participants with high p ‐tau217. We will explore whether this discrepancy is due to disease or peripheral interference with the N‐terminal binding in p ‐tau assays.
Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826
Castellino, Sharon M., Li, H., Herrera, Alex F. , LeBlanc, Michael, Parsons, SK, Unger, Joseph M., Punnett, Angela , Hodgson, David, Keller, FG, Drachtman, Richard A. , Lamble, Adam J. , Doan, Andrew , Rutherford, Sarah C. , Little, Richard F. , Song, Joo Y., Smith, Sonali M. , Friedberg, Jonathan W. , Kelly, Kara M., Unger, Joseph M. , Castellino, Sharon M. , Parsons, Susan K. , Hodgson, David , Keller, Frank G. , Castellino, Sharon , Li, Hongli , K Parsons, Susan , Unger, Joseph M , Hodgson, David , Keller, Frank G , Lamble, Adam , Doan, Andrew , Rutherford, Sarah C , Evens, Andrew M , Little, Richard F , Smith, Malcolm A , Hoppe, Bradford S , Song, Joo Y , Kelly, Kara M , LeBlanc, Michael L., Forlenza, Christopher J. , Evens, Andrew M. , Smith, Malcolm A. , Hoppe, Bradford S. , Kelly, Kara M.

Mayo Clinic

Journal of Clinical Oncology | January 9, 2026 | Volume: 44 | Issue: 6 | Pages: 449-454

10.1200/jco-25-00203 | PMID 41512237 Get It

We present a subset analysis on the adolescent cohort of the S1826 randomized phase three trial, comparing nivolumab, doxorubicin, vinblastine, dacarbazine (N-AVD) to brentuximab vedotin-AVD (BV-AVD) in newly diagnosed advanced-stage (AS, stages III and IV) classic Hodgkin lymphoma (cHL). Among 994 patients enrolled, 24% (n = 240) were age 12-17 years. The 3-year progression-free survival (PFS) was significantly higher in the N-AVD group (93% [95% CI, 87 to 96]) compared with the BV-AVD group (82% [95% CI, 73 to 88]; hazard ratio, 0.37 [95% CI, 0.17 to 0.80]). One N-AVD and two BV-AVD patients received protocol-specified residual site radiotherapy (RT). Rates of febrile neutropenia and sepsis were low in both groups. Severe immune-related adverse events were infrequent, although thyroid dysfunction was seen in 7% with N-AVD. Sensory neuropathy (grade ≥2) was more frequent with BV-AVD (14% v 7%) by clinician report. Although premature discontinuation of therapy was reported in 12 N-AVD patients and four BV-AVD patients, no PFS events were noted in the N-AVD group. Patient-reported outcomes indicated less toxicity with N-AVD. N-AVD demonstrated high 3-year PFS in adolescents with AS cHL, with minimal RT use. S1826 exemplifies the benefits of harmonized clinical trial protocols, resulting in timely access to novel agents for adolescents.
MTAP Deletion in Oncogenesis: A Synthetic Lethality Scenario
Rodon, Jordi, Johnson, Melissa L. , George, Ben , Shah, Pooja A. , Arbour, Kathryn C. , Rodon, Jordi , Johnson, Melissa L

Mayo Clinic

Cancer Research | January 9, 2026 | Volume: 86 | Issue: 7 | Pages: 1558-1569

10.1158/0008-5472.can-25-2126 | PMID 41512197 Get It

Abstract Homozygous deletions in the gene encoding methylthioadenosine phosphorylase (MTAP) occur in ∼10% of patients with cancer, including up to 45% in some tumor types, and may be associated with poor prognosis. MTAP deficiency causes accumulation of its catabolic target methylthioadenosine (MTA) that outcompetes S-adenosyl methionine (SAM) for binding to protein arginine methyltransferase 5 (PRMT5), partially inhibiting PRMT5 activity as a posttranslational regulator of a variety of critical cellular functions. Prior anticancer treatments developed to target PRMT5 exhibited high rates of dose-limiting hematologic toxicities because of a lack of selectivity for tumor cells. More recently, several agents have been developed that exploit the vulnerability of MTAP-deleted cancer cells to further inhibition of the PRMT5 pathway, selectively inducing synthetic lethality in those cancer cells. MTA-cooperative PRMT5 inhibitors such as BMS-986504/MRTX1719 and AMG 193 target the PRMT5–MTA complex, whereas inhibitors of the SAM synthetase methionine adenosyl transferase 2A, such as IDE397, deprive PRMT5 of its methyl donor SAM. In this review article, we summarize the mechanisms of action, preclinical data, and clinical data available thus far for these novel classes of oncology precision medicine and discuss potential future directions relevant to MTAP deletion as a promising synthetic lethal vulnerability for cancer therapy.
Using the Quality Outcomes Database to Identify Minimum Clinically Important Differences for Patients With Cervical Spondylotic Myelopathy
Asher, Anthony L., Lakomkin, Nikita, Mummaneni, Praveen V., Michalopoulos, Giorgos D., Johnson, Sarah E. , Park, Paul J. , Gottfried, Oren N., Potts, Eric A. , Foley, Kevin T. , Wang, Michael Y., Knightly, John J. , Shaffrey, Christopher I., Virk, Michael S. , Fu, Kai-Ming, Tumialán, Luis M. , Turner, Jay D., Uribe, Juan S., Upadhyaya, Cheerag D., Shaffrey, Mark E., Coric, Domagoj , Chou, Dean, Haid, Regis W., Ef, Bisson, Bydon, Mohamad, Katsos, Konstantinos, Asher, Anthony L. , Lakomkin, Nikita , Mummaneni, Praveen V. , Michalopoulos, Giorgos D. , Park, Paul, Asher, Anthony M. , Katsos, Konstantinos, Wang, Michael Y. , Shaffrey, Christopher I. , Fu, Kai-Ming, Turner, Jay D. , Uribe, Juan S. , Chou, Dean , Bisson, Erica F. , Bydon, Mohamad

Mayo Clinic

Neurosurgery | January 9, 2026 | Volume: 98 | Issue: 6 | Pages: 1347-1358

10.1227/neu.0000000000003902 | PMID 41511085 Get It

BACKGROUND AND OBJECTIVES: Minimum clinically important differences (MCIDs) for patient-reported outcome metrics (PROMs) in patients with cervical spondylotic myelopathy (CSM) lack consensus on the most appropriate calculation method. This retrospective study aimed to identify the optimal MCIDs for commonly used PROMs in CSM. METHODS: The CSM database from the Quality Outcomes Database SpineCORe Study Group was analyzed. Baseline, 3-month, and 24-month PROM values for Neck Disability Index (NDI), 5-dimension Euro-quality of life (EQ-5D) in quality-adjusted life years, modified Japanese Orthopaedic Association (mJOA) score, and neck/arm pain numeric rating scale (NRS) were collected. MCIDs were calculated for each PROM using previously validated techniques. MCID values were compared using the area under the curve (AUC) with the North American Spine Society satisfaction scale as an anchor. RESULTS: A total of 1141 patients with CSM undergoing surgery were included in this analysis. Improvement of ≥30% from baseline was the optimal MCID for NDI and neck/arm NRS. At 24 months, the optimal percentage cutoff MCID for these instruments resulted in AUCs of 0.76, 0.72, and 0.67, similar to the 30% improvement method, with AUCs of 0.73, 0.71, and 0.67, respectively. Numeric cutoffs (0.065 at 3 months; 0.149 at 24 months) were the superior MCIDs for EQ-5D. For mJOA score, a severity-adjusted MCID outperformed other methods, yielding an AUC of 0.67 at 24 months. MCIDs were achieved in 63% of patients for NDI, 59% for neck pain NRS, 61% for arm pain NRS, 52% for EQ-5D, and 59% for mJOA score at 24 months. CONCLUSION: Using the Quality Outcomes Database SpineCORe data set, we defined optimal MCIDs for key PROMs in CSM. A ≥30% improvement from baseline was optimal in NDI and arm/neck NRS. An absolute numeric cutoff was superior for EQ-5D (0.149 at the 24-month follow-up). A severity-adjusted MCID performed best for mJOA score. These redefined benchmarks better capture the treatment impact and guide care decisions for patients with CSM.
Prognostic Factors Among Patients Receiving Microaxial Flow Pump for Acute Myocardial Infarction-Related Cardiogenic Shock: A Systematic Review and Meta-Analysis
Parlow, Simon, Jung, Richard G. , Almoosawy, Sayed Abdulmotaleb , Lepage-Ratte, Melissa Fay , Durr, Michael, Mathieu, Marie-Eve , Santo, Pietro Di, Motazedian, Pouya, Sterling, Lee H., Abdel-Razek, Omar, Fan, Eddy, Thiele, H., Price, Susanna, Diepen, Sean van, Visintini, Sarah , Basir, Mir B., Kapur, Navin K. , Hibbert, Benjamin, Tran, Alexandre, Møller, J. T., Rochwerg, B., Mathew, R., Parlow, Simon , Fernando, Shannon M , Parlow, Simon , Durr, Michael-Roy R, Mathieu, Marie-Eve, Santo, Pietro Di , Motazedian, Pouya , Abdel‐Razek, Omar , Fan, Eddy , Price, Susanna , Diepen, Sean van , Basir, Mir B. , Hibbert, Benjamin , Tran, Alexandre , Rochwerg, Bram , Mathew, Rebecca , Fernando, Shannon M.

Mayo Clinic

Critical Care Medicine | January 8, 2026 | Volume: 54 | Issue: 3 | Pages: 584-593

10.1097/ccm.0000000000007013 | PMID 41504526 Get It

Objectives: To identify factors associated with short-term mortality among patients receiving microaxial flow pump (mAFP) therapy for acute myocardial infarction-related cardiogenic shock (AMI-CS). Data Sources: We searched four databases (MEDLINE, Embase, CENTRAL, and Scopus) from January 1, 2004, to January 1, 2025. Study Selection: We selected English-language studies that included adults with AMI-CS receiving mAFP and evaluated factors associated with short-term mortality. We excluded patients receiving concurrent venoarterial extracorporeal membrane oxygenation, as well as studies that solely included patients presenting with out-of-hospital cardiac arrest. Data Extraction: Two authors performed citation screening and data extraction. For each factor evaluated in at least two studies, we performed meta-analyses of adjusted odds ratios (aORs) using a random-effects model. Risk of bias was evaluated using the Quality in Prognosis Studies tool, and the certainty of evidence was evaluated using Grading of Recommendations, Assessment, Development, and Evaluations methodology. Data Synthesis: Our primary analysis included 18 studies, encompassing 20,617 patients. Median short-term mortality across studies was 50.7% (interquartile range 38.4–55.3%). Factors associated with short-term mortality based on high-certainty evidence included: increased age (aOR, 1.04 per year [95% CI, 1.03–1.05 per year] or ≥ 65 yr (aOR, 2.42 yr [95% CI, 0.77–7.64 yr]), female sex (aOR, 1.26 [95% CI, 1.09–1.45]), higher body mass index (aOR, 1.05 per point [95% CI, 1.04–1.07 per point]), higher heart rate (aOR, 1.02 per beats/min [95% CI, 1.01–1.02 per beats/min]), higher serum creatinine (aOR, 1.35 per mg/dL [95% CI, 1.08–1.70 per mg/dL]), mechanical ventilation (aOR, 2.53 [95% CI, 1.82–3.53]), vasopressors (aOR, 1.52 [95% CI, 1.11–2.08] for any vasopressors and aOR, 1.37 [95% CI, 1.18–1.58] per each vasopressor), presentation with ST-elevation myocardial infarction (aOR, 1.59 [95% CI, 1.11–2.26]), cardiac arrest (aOR, 2.85 [95% CI, 2.22–3.64]), and hypoxic-ischemic brain injury (aOR, 5.36 [95% CI, 3.03–9.47]). Conclusions: We identified several prognostic factors associated with short-term mortality in AMI-CS patients receiving mAFP support. This work may help inform clinicians, patients, and families regarding utilization of mAFP in AMI-CS.
Multiple Myeloma, Version 5.2026, NCCN Clinical Practice Guidelines In Oncology
Kumar, Shaji K., Adekola, Kehinde , Anderson, Larry , Costello, C. L., D’Angelo, Christopher R. , Elsedawy, Noura, Godara, Amandeep , Godby, Kelly, Hillengass, J, Holmberg, Leona, Htut, Myo , Huff, Carol Ann , Hultcrantz, Malin , Kang, Yubin , Larson, Sarah, Lee, Hans Chulhee, Liedtke, Michaela , Martin, Thomas, Omel, James, Robinson, Timothy J., Rosenberg, Aaron, Sherbenou, Daniel, Suvannasankha, Attaya, Valent, Jason , Varshavsky‐Yanovsky, Asya, Ye, J Christine, Kovach, Emily, Kumar, Rashmi , Kumar, Shaji , Callander, Natalie S. , Baljević, Muhamed , Baz, Rachid , Campagnaro, Erica , Costello, Caitlin , Derman, Benjamin A. , Devarakonda, Srinivas , Hillengass, Jens, Holmberg, Leona , Kang, Yubin , Larson, Sarah, Lee, Hans C. , Rosenberg, Aaron , Sarosiek, Shayna , Schroeder, Mark A. , Sherbenou, Daniel W , Suvannasankha, Attaya , Valent, Jason Neil , Vogl, Dan T. , Kovách, E

Mayo Clinic

Journal of the National Comprehensive Cancer Network | January 8, 2026 | Volume: 24 | Issue: 1 | Pages: No page available

10.6004/jnccn.2026.0001 | PMID 41671464 Get It

The treatment landscape for multiple myeloma (MM) is evolving rapidly and includes several new options. The management must be tailored to the individual. The NCCN Guidelines for MM provide a framework to base decisions regarding diagnosis, workup, treatment, and follow-up of both newly diagnosed and previously treated relapsed/refractory MM. This manuscript outlines the recommendations from NCCN Guidelines for MM specific to newly diagnosed MM (NDMM).